×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APVO – aptevo therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/12
01:24 pm
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.
11/10
08:18 am
apvo
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
Medium
Report
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
11/7
01:12 am
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.
Neutral
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.
10/8
08:38 am
apvo
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter [Yahoo! Finance]
Low
Report
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter [Yahoo! Finance]
10/3
03:30 pm
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.
9/20
09:50 am
apvo
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Zacks Research to a "hold" rating.
9/18
06:43 am
apvo
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
High
Report
Aptevo Therapeutics (NASDAQ:APVO) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/26
06:06 am
apvo
Form EFFECT Aptevo Therapeutics Inc.
Medium
Report
Form EFFECT Aptevo Therapeutics Inc.
11/25
04:48 pm
apvo
Form 424B4 Aptevo Therapeutics Inc.
Medium
Report
Form 424B4 Aptevo Therapeutics Inc.
11/12
04:33 pm
apvo
Form 4 Aptevo Therapeutics Inc. For: Nov 10 Filed by: Grant Grady III
Medium
Report
Form 4 Aptevo Therapeutics Inc. For: Nov 10 Filed by: Grant Grady III
11/7
01:39 pm
apvo
Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: BANK OF AMERICA CORP /DE/
Low
Report
Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: BANK OF AMERICA CORP /DE/
11/6
04:20 pm
apvo
Form 10-Q Aptevo Therapeutics Inc. For: Sep 30
Low
Report
Form 10-Q Aptevo Therapeutics Inc. For: Sep 30
11/6
04:08 pm
apvo
Form 8-K Aptevo Therapeutics Inc. For: Nov 06
Neutral
Report
Form 8-K Aptevo Therapeutics Inc. For: Nov 06
10/30
04:31 pm
apvo
Form 8-K Aptevo Therapeutics Inc. For: Oct 30
High
Report
Form 8-K Aptevo Therapeutics Inc. For: Oct 30
10/6
04:26 pm
apvo
Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: BANK OF AMERICA CORP /DE/
High
Report
Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: BANK OF AMERICA CORP /DE/
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/10
Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
20.5%
3/16 Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial 19.1%
4/13 Form 8-K Aptevo Therapeutics Inc. For: Apr 13 15.2%
10/3 Form 8-K Aptevo Therapeutics Inc. For: Oct 03 11.6%
3/18 Aptevo Therapeutics Inc (NASDAQ: APVO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
11/4 Form 8-K Aptevo Therapeutics Inc. For: Nov 01 8.8%
2/28 Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million 7.5%
11/8 Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting 7.4%
4/23 Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.7%
8/19 Form 4 Aptevo Therapeutics Inc. For: Aug 16 Filed by: Maddux Randy Joe 5.6%
3/16 Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial 19.1%
4/13 Form 8-K Aptevo Therapeutics Inc. For: Apr 13 15.2%
10/3 Form 8-K Aptevo Therapeutics Inc. For: Oct 03 11.6%
3/18 Aptevo Therapeutics Inc (NASDAQ: APVO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
11/4 Form 8-K Aptevo Therapeutics Inc. For: Nov 01 8.8%
2/28 Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million 7.5%
11/8 Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting 7.4%
4/23 Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.7%
8/19 Form 4 Aptevo Therapeutics Inc. For: Aug 16 Filed by: Maddux Randy Joe 5.6%
TOP News Decliners
2/13
Form SC 13G/A Aptevo Therapeutics Inc. Filed by: RENAISSANCE TECHNOLOGIES LLC
-20.0%
3/13 Form 8-K Aptevo Therapeutics Inc. For: Mar 11 -14.5%
8/12 Form 424B5 Aptevo Therapeutics Inc. -13.5%
3/2 Form 8-K Aptevo Therapeutics Inc. For: Feb 28 -12.3%
1/31 Form PRE 14A Aptevo Therapeutics Inc. For: Mar 11 -12.0%
8/9 Q2/2019 6/30/2019 EPS -0.300 ZacksConsensus -0.380 ActVsEst 0.080 - Beat -11.2%
3/5 Aptevo Therapeutics Inc (NASDAQ: APVO) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.0%
10/16 Form 8-K Aptevo Therapeutics Inc. For: Oct 11 -6.9%
3/25 Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update -6.9%
7/25 Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials -6.4%
3/13 Form 8-K Aptevo Therapeutics Inc. For: Mar 11 -14.5%
8/12 Form 424B5 Aptevo Therapeutics Inc. -13.5%
3/2 Form 8-K Aptevo Therapeutics Inc. For: Feb 28 -12.3%
1/31 Form PRE 14A Aptevo Therapeutics Inc. For: Mar 11 -12.0%
8/9 Q2/2019 6/30/2019 EPS -0.300 ZacksConsensus -0.380 ActVsEst 0.080 - Beat -11.2%
3/5 Aptevo Therapeutics Inc (NASDAQ: APVO) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.0%
10/16 Form 8-K Aptevo Therapeutics Inc. For: Oct 11 -6.9%
3/25 Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update -6.9%
7/25 Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials -6.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: